Intelcom has supported the CHUM Foundation for several years, as part of its commitment to contributing to the well-being of the community at large. Today, this Quebec-based company has decided to expand its commitment to more fully reflect its vision: supporting projects with a strong human, scientific and social impact that can truly change lives. This leader in last-mile delivery has now pledged a $1.25 million donation over five years, focused on two areas that are key at the CHUM—mental health and immunopathology.
Mental health: Adapting care to multiple realities
Intelcom’s generosity will help accelerate the treatment of substance-abuse disorders. Currently, the lack of adapted treatment is leaving too many people—many of them young—without effective solutions and therefore, likely to experience rapid deterioration of their physical and mental health. The goal is to quickly offer this population personalized solutions that combine recognized psychotherapies with adapted medication, all the while developing robust clinical tools to harmonize all practices and enrich quality of care across the network. This donation will also make possible the implementation of a mobile app targeting youth who have experienced their first psychotic episode. This app is designed to help them better manage their cannabis consumption, and features interactive content and tools to help prevent a relapse.
Immunopathology: Targeted therapies that improve daily life
IIntelcom also wants to support the development of precision therapeutic strategies to better care for patients suffering from complex diseases, such as cystic fibrosis (mucoviscidose), which is the most common potentially fatal genetic disease among children and young adults in Canada. Although new medications have advanced research and available treatments in recent years, the effectiveness of these medications is still variable and some patients do not respond to treatment.
The goal of supporting these initiatives is to better prevent the progression of disease and develop solutions that are adapted to each type of mutation, to each profile, at any stage of the disease, so that lung function, as well as the patient’s quality of life, is sustainably improved.
“We were deeply impressed by the CHUM’s standing as a pillar of the healthcare system. We know that investing in medical research has a genuine multiplier effect: each breakthrough not only improves available care, it also generates long-term benefits for our entire community. In donating to the CHUM Foundation, we are supporting teams that are expanding the boundaries of innovation and contributing to initiatives that offer patients a real prospect for hope, for well-being—and that is a privilege.”
— Jean‑Sébastien Joly, President and CEO, Intelcom
Thank you from the bottom of our hearts!
